Home・Akcijų sąrašas・Ocular Therapeutix Inc

Ocular Therapeutix Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

10.02 -0.69

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.65

Max

10.09

Pagrindiniai rodikliai
By Trading Economics
Pajamos	9.8M -79M
Pardavimai	2.7M 13M
Pelnas, tenkantis vienai akcijai	-0.35
Pelno marža	-584.512
Darbuotojai	325
EBITDA	8.6M -76M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+155.25% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-03

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	137M 2B
Ankstesnė atidarymo kaina	10.71
Ankstesnė uždarymo kaina	10.02

Naujienos nuotaikos

By Acuity

38%

62%

135 / 340 reitingas Healthcare

Ocular Therapeutix Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-14 19:46; UTC

Ocular Therapeutix Inc shares are lower amid a decline in the Pharmaceuticals sub-sector. The stock has traded down since Thursday's close.

2026-08-13 23:16; UTC

Ocular Therapeutix Inc's shares are lower in after-market hours, reflecting a slight decline since Thursday's close. No specific news was identified for this movement.

2026-08-12 20:01; UTC

Ocular Therapeutix Inc shares are higher in Wednesday's session, with elevated trading volume. The stock remains above its 20-day moving average.

2026-08-11 23:21; UTC

Ocular Therapeutix Inc shares fell during after-market hours, reaching a session low before slightly recovering. Broader market dynamics may be influencing this decline.

2026-08-10 20:06; UTC

Ocular Therapeutix Inc is trading higher, recovering above its 20-day moving average amid a broader trend of three consecutive sessions finishing higher.

2026-08-07 21:01; UTC

Ocular Therapeutix Inc shares are higher in after-market hours, continuing an upward trend after three consecutive sessions of gains.

2026-08-06 20:06; UTC

Ocular Therapeutix Inc shares are higher during Thursday's session, recovering from an earlier dip despite trading below their 20-day moving average.

2026-08-05 21:03; UTC

Ocular Therapeutix Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains under pressure.

2026-08-03 20:06; UTC

Social Media

News

Ocular Therapeutix shares rise after reporting Q2 revenue of $13.5 million, exceeding estimates, and announcing plans for a new drug application for AXPAXLI.

2026-07-31 21:01; UTC

Ocular Therapeutix Inc shares are lower in after-market hours with no specific news identified. Broader market conditions reflect mixed performance amid rising inflation concerns.

2026-07-30 19:39; UTC

Ocular Therapeutix shares are higher today, continuing an upward trend since Wednesday. The U.S. Dollar Index decline may be influencing broader market dynamics.

2026-07-28 19:06; UTC

News

Ocular Therapeutix shares are lower amid broader market volatility and regulatory challenges, reaching a session low earlier today.

2026-07-27 21:01; UTC

Ocular Therapeutix Inc. shares are higher in after-market trading, reaching a peak shortly after the session began amid improved European market sentiment.

2026-07-22 18:36; UTC

Social Media

Ocular Therapeutix is presenting at the HC Wainwright conference, but shares are declining and remain below their 20-day moving average.

2026-07-21 23:41; UTC

Ocular Therapeutix Inc shares rose in after-market trading, reaching their highest cumulative return of the day. The stock remains below its 20-day moving average.

2026-07-20 19:46; UTC

Social Media

Ocular Therapeutix shares are lower today, continuing a downward trend. Early gains were followed by a pullback amid uncertain investor sentiment.

Akcijų palyginimas

Kainos pokytis

Ocular Therapeutix Inc Prognozė

Kainos tikslas

By TipRanks

155.25% į viršų

12 mėnesių prognozė

Vidutinis 25.78 USD 155.25%

Aukščiausias 31 USD

Žemiausias 18 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ocular Therapeutix Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Ocular Therapeutix Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

135 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.